コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ts an evolving treatment strategy in chronic plaque psoriasis.
2 es with the classic subtype of Western large plaque psoriasis.
3 ies, for the treatment of moderate-to-severe plaque psoriasis.
4 alimumab in patients with moderate-to-severe plaque psoriasis.
5 I 655066 in patients with moderate-to-severe plaque psoriasis.
6 option for patients with moderate-to-severe plaque psoriasis.
7 o and etanercept in the treatment of chronic plaque psoriasis.
8 s a treatment for moderate-to-severe chronic plaque psoriasis.
9 ntibody, in patients with moderate-to-severe plaque psoriasis.
10 valuated in patients with moderate-to-severe plaque psoriasis.
11 umab in children and adolescents with severe plaque psoriasis.
12 I-s, saSPI-s, and SPI-p in 100 patients with plaque psoriasis.
13 efficacious treatment for moderate-to-severe plaque psoriasis.
14 ody, for the treatment of moderate-to-severe plaque psoriasis.
15 dren and adolescents with moderate-to-severe plaque psoriasis.
16 hibitor, in patients with moderate-to-severe plaque psoriasis.
17 dren and adolescents with moderate-to-severe plaque psoriasis.
18 er polymorphisms of the MIF gene and chronic plaque psoriasis.
19 of patients with moderate-to-severe chronic plaque psoriasis.
20 easures, in patients with moderate to severe plaque psoriasis.
21 cept, a TNF antagonist, for the treatment of plaque psoriasis.
22 disease expression in patients with chronic plaque psoriasis.
23 in pivotal phase III trials in patients with plaque psoriasis.
24 s are present in the skin lesions of chronic plaque psoriasis.
26 ed lesional skin of 13 patients with chronic plaque psoriasis and 12 patients with other inflammatory
27 89 individuals with mild-to-moderate chronic plaque psoriasis and 54 without psoriasis, recruited at
28 nd FAS, were decreased in both Western large plaque psoriasis and psoriasis with accompanying arthrit
29 tekinumab trial suggesting efficacy for both plaque psoriasis and psoriatic arthritis, our case serie
30 ed 1106 eligible adult patients with chronic plaque psoriasis and randomly assigned them to the four
32 and active plaque psoriasis than in chronic plaque psoriasis and sebopsoriasis; i.e., the extent of
33 t guselkumab may be an effective therapy for plaque psoriasis and that control of psoriasis can be ac
35 nty-eight UK caucasian patients with chronic plaque psoriasis, and a control panel of 401 UK caucasia
36 targeting LFA-1 for the treatment of chronic plaque psoriasis, and natalizumab (Tysabri/Antegren) tar
37 ion, we defined Asian small and intermediate plaque psoriasis as psoriasis subtypes and compared thei
39 older, had a confirmed diagnosis of chronic plaque psoriasis at least 6 months before baseline (rand
40 ars or older with moderate-to-severe chronic plaque psoriasis (body surface area involvement >/=10%,
41 sitizing agent protoporphyrin IX in areas of plaque psoriasis by monitoring of the fluorescence emiss
42 with type 1 (onset before age 40 y) chronic plaque psoriasis compared to healthy controls and also m
43 ponse in the treatment of moderate to severe plaque psoriasis compared with patients who received pla
44 hat blood samples from patients with chronic plaque psoriasis contained significantly higher titers o
47 8 years or older, had a diagnosis of chronic plaque psoriasis for at least 6 months before baseline,
48 ty trial, adult patients with chronic stable plaque psoriasis (for >/=12 months) who were candidates
49 o-thirds of patients with moderate-to-severe plaque psoriasis harbour CD4(+) and/or CD8(+) T cells sp
50 rapy resulted in significant improvements in plaque psoriasis in subjects with moderate-to-severe dis
54 design and included 38 patients with chronic plaque psoriasis measuring less than or equal to 100 cm2
55 g/kg in children and adolescents with severe plaque psoriasis provided significant improvements in PA
56 Western large plaque psoriasis, Asian small plaque psoriasis revealed limited psoriasis spreading, b
57 t a subpopulation of CD4+ T cells in chronic plaque psoriasis skin lesions produces interferon-gamma
58 ks is associated with improvement in chronic plaque psoriasis; some patients have a sustained clinica
61 ore important in the pathogenesis of chronic plaque psoriasis than has previously been recognized, an
62 s more disrupted in erythrodermic and active plaque psoriasis than in chronic plaque psoriasis and se
63 eport 4 cases of ustekinumab monotherapy for plaque psoriasis that resulted in disabling flares of kn
65 142 patients with chronic moderate-to-severe plaque psoriasis to receive subcutaneous injections of 1
66 A-1 (efalizumab; Raptiva for severe forms of plaque psoriasis) to prevent extravasation of inflammato
67 trial, 320 patients with moderate-to-severe plaque psoriasis underwent randomization to treatment wi
68 es of psoriasis are recognised, with chronic plaque (psoriasis vulgaris) accounting for 90% of cases.
69 r 3,523 biologic-naive patients with chronic plaque psoriasis were compared using survival analysis t
73 matory cytokines were lower in Western large plaque psoriasis, whereas T cells and dendritic cells in
74 r adults (>18 years) with moderate to severe plaque psoriasis who are candidates for phototherapy or
75 was collected from 374 patients with chronic plaque psoriasis who had been treated with methotrexate.
76 atients (aged >/=4 to <18 years) with severe plaque psoriasis who had not responded to topical therap
77 is effective in treatment of limited chronic plaque psoriasis with a satisfactory safety profile.
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。